7.9 C
New York
Friday, April 19, 2024

Credit Suisse Downgrades Sucampo Pharmaceuticals To Underperform

Courtesy of Benzinga.

Related SCMP
Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest EPS
19 Lesser-Known Biotech Stocks With Robust Drug Pipelines
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report (Seeking Alpha)

Analysts at Credit Suisse downgraded Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) from Neutral to Underperform.

The price target for Sucampo Pharmaceuticals has been raised from $10.00 to $13.00.

Sucampo Pharmaceuticals shares have gained 81.15% over the past 52 weeks, while the S&P 500 index has surged 14.02% in the same period.

Sucampo Pharmaceuticals’ shares fell 3.87% to close at $15.38 on Friday.

Latest Ratings for SCMP

Date Firm Action From To
Mar 2015 Credit Suisse Downgrades Neutral Underperform
Feb 2015 Cantor Fitzgerald Maintains Buy
Oct 2014 Maxim Group Upgrades Hold Buy

View More Analyst Ratings for SCMP
View the Latest Analyst Ratings

Posted-In: Credit SuisseDowngrades Analyst Ratings

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,353FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x